Daily close, T-120 (12/2/24) through T+5. Run-up high $10.82 on 1/13/25, low $5.43 on 4/11/25 (T-120 to T-1). FDA decision 5/19/25. Historical price action, not a forecast.
Positioning before the decision
On May 5, 2025, 14 days before the decision date, at-the-money options priced a move of ±20.8% through May 23, 2025 (the first listed expiry after the decision; ATM implied volatility 116%). The stock closed +15.0% at the first close across the decision and +7.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for NUVAXOVID on May 19, 2025. The primary source is linked on this page.
What was NUVAXOVID under FDA review for?
The application covered Covid-19. The FDA approved the application on May 19, 2025.
How did NVAX stock react to the FDA decision?
On the decision day NVAX moved +15.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.